Nicole Barna

Nicole Barna, listed as chief executive, appears in our data through filings on Codiak BioSciences, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 20 January 2022 to 29 March 2023, the count stands at 9 filings.

The open-market side counts 1 purchase for €44k alongside 5 sales for €4,404. The net balance comes to €40k on the buying side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 3 option exercises. In 2023 alone, the filings show no purchases and 5 sales.

The latest filing, published on 30 March 2023, reports an open-market sale of €296 in Codiak BioSciences, Inc. The most recent open-market purchase was published on 7 February 2022, 1,720 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.